News >

Real-World Evidence Reassuring for PARP Inhibitor Use in Ovarian Cancer

Caroline Seymour
Published: Friday, Nov 22, 2019

Floor J. Backes, MD

Floor J. Backes, MD

PARP inhibitors, with proper patient selection, are as tolerable as they are effective, according to Floor J. Backes, MD. These agents are now being explored in combination to further improve outcomes for patients with advanced ovarian cancer.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication